Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 8Neoplasms 4Recurrence 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hepatic Insufficiency 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 101Cyclophosphamide 51Prednisone 32Doxorubicin 32Vincristine 31Gemcitabine 29Lenalidomide 27Oxaliplatin 22Bendamustine Hydrochloride 19ibrutinib 16fludarabine 16tafasitamab 12polatuzumab vedotin 12venetoclax 11tisagenlecleucel 11obinutuzumab 11loncastuximab tesirine 9Etoposide 9zanubrutinib 8Prednisolone 8Injections 8Ifosfamide 8Carboplatin 8selinexor 7pembrolizumab 7durvalumab 7axicabtagene ciloleucel 7Dexamethasone 7tazemetostat 6parsaclisib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large B-Cell, Diffuse × copanlisib × Clear all
NCT02391116 2019-01-04

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Bayer

Phase 2 Completed
67 enrolled 29 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡